Your Location：Home >Products >Pharmaceutical >960404-48-2
Purity:99%
|
960404-48-2 Name |
|
|
Name |
Dapagliflozin propanediol monohydrate |
|
Synonym |
(2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL COMPOUND WITH (S)-PROPANE-1,2-DIOL (1:1) HYDRATE;BMS 512148 (2S)-1,2-propanediol;CS-1307;Dapagliflozin (S)-Propylene Glycol Hydrate;Dag column net a water glycol;Dapagliflozin propanediol hydrate;Dapagliflozin,(2S)-1,2-propanediol, hydrate (1:1:1);Dapagliflozin ((2S)-1,2-propanediol, hydrate)###461432-26-8###Dapagliflozin |
|
960404-48-2 Biological Activity |
|
|
Related Catalog |
Signaling Pathways >> Membrane Transporter/Ion Channel >> SGLT Research Areas >> Metabolic Disease |
|
960404-48-2 Chemical & Physical Properties |
|
|
Melting point |
74 - 78°C |
|
Molecular Formula |
C24H35ClO9 |
|
Molecular Weight |
502.982 |
|
PSA |
149.07000 |
|
LogP |
1.13960 |
|
Exact Mass |
502.196960 |
|
storage temp. |
-20°C Freezer |
Dapagliflozin Propanediol Hydrate is an SGLT2 inhibitor, which can be used for the treatment of diabetes. The conventional formulation of dapagliflozin was developed as dapagliflozin propanediol monohydrate (DAP-PDH), a crystalline hydrate form of dapagliflozin with (S)-propylene glycol and water. Dapagliflozin propanediol monohydrate (DPG), is a novel sodium cotransporter type 2 (SGLT-2) inhibitor.
The optimized analytical technique was subjected to validation (according to ICHQ1 guideline) and was observed to be highly reproducible with greater level of specificity, and therefore can be practiced for routine quantification of sitagliptin and dapagliflozin propanediol monohydrate from proposed formulation.
Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
(S)-1,2-Propanediol
(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol
dapagliflozin (S) propylene glycol hydrate
| Conditions | Yield |
|---|---|
|
(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; With triethylsilane; boron trifluoride diethyl etherate; In acetonitrile; at 0 - 25 ℃; Inert atmosphere;
(S)-1,2-Propanediol; With water; In tert-butyl methyl ether;
|
60% |
dapagliflozin
(S)-1,2-Propanediol
dapagliflozin (S) propylene glycol hydrate
| Conditions | Yield |
|---|---|
|
With water; In tert-butyl methyl ether; cyclohexane; for 1h; Product distribution / selectivity;
|
4% |
|
With water; In methanol; Isopropyl acetate; cyclohexane; at 5 - 20 ℃; for 1 - 22.1667h; Product distribution / selectivity;
|
|
|
With water; In methanol; Isopropyl acetate; cyclohexane; at 5 ℃; for 1 - 22h; Product distribution / selectivity;
|
dapagliflozin
(S)-1,2-Propanediol
CAS：2094-72-6
CAS：5451-09-2
CAS：461432-26-8
CAS：41753-43-9
